Armata Pharmaceuticals, Inc.

ARMP NYSE SEC CIK 921114
Follow Armata Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
EPS, diluted $1.15 +255.4% vs same quarter last year
Operating cash flow −$5.5M −28.3% vs same quarter last year
Operating income −$7.4M +5.1% vs same quarter last year
Net income by quarter
$2.6M
−$6.5M
−$16.3M
−$26.7M
−$124.3M
−$115.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
−$200M−$150M−$100M−$50M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$173.8M
FY24−$18.9M
FY23−$69M
FY22−$36.9M
FY21−$23.2M
FY20−$22.2M
FY19−$19.5M
FY18−$16.7M
FY17−$12.8M
FY16−$18.8M
FY15−$516K
FY14-
FY13−$64.6M
FY12-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$26.3M
FY24−$39.4M
FY23−$55.6M
FY22−$34.7M
FY21−$24.9M
FY20−$19.1M
FY19−$15.8M
FY18−$11.5M
FY17−$9.3M
FY16−$10.9M
FY15−$10M
FY14−$13.8M
FY13−$6.4M
FY12-